Zobrazeno 1 - 10
of 143
pro vyhledávání: '"E. von Schoultz"'
Autor:
Hua Zhang, B. von Schoultz, Mia Fahlén, Lena Sahlin, E. von Schoultz, L. Löfgren, Britt Masironi
Publikováno v:
Gynecological Endocrinology. 33:353-358
Stromal factors have been identified as important for tumorigenesis and metastases of breast cancer. From 49 premenopausal women, samples were collected from benign or malignant tumors and the seemingly normal tissue adjacent to the tumor. The factor
Publikováno v:
Climacteric. 12:478-489
Objectives To investigate the attitudes of breast cancer patients who accepted or declined participation in a randomized trial with hormone replacement therapy that might increase their risk of recurrence (the Stockholm trial). Methods A total of 115
Autor:
M. Linderholm, Jonas Bergh, Barbro Linderholm, Göran Elmberger, U. Johansson, H. Hellborg, Lambert Skoog, Jenny Bergqvist, E. von Schoultz
Publikováno v:
Medical Oncology. 26:480-490
Purpose: To investigate the possible correlation between expression of HER2 and vascular endothelial growth factor (VEGF), and to determine the predictive value of these factors in patients receiving adjuvant endocrine therapy including the group wit
Autor:
B. Nilsson, N. Wilking, Lambert Skoog, L. Löfgren, E. von Schoultz, E. Isaksson Friman, M. Mahlman
Publikováno v:
Acta Oncologica. 46:194-198
Postmenopausal hormone therapy (HT) may increase breast cancer risk and influence tumor characteristics. We investigated 321 postmenopausal women aged 50-65 years, with breast cancer, diagnosed and treated at Radiumhemmet, Karolinska Hospital, during
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 99:76-79
Individual women differ with respect to their sensitivity to estrogen and serum levels of sex hormone-binding globulin (SHBG) may reflect the individual response. We found a significant correlation between estrogen receptor (ER) concentrations in bre
Publikováno v:
Journal of Clinical Oncology. 22:3694-3699
Purpose To examine the effects on bone mineral density of 2 years of treatment with a luteinizing hormone-releasing hormone (LHRH) agonist alone or in combination with tamoxifen or tamoxifen alone in premenopausal breast cancer. Patients and Methods
Autor:
Birgitta Wallberg, Lars-Erik Rutqvist, Tommy Fornander, B. von Schoultz, E. von Schoultz, L. Löfgren, K. Carlström, N. Wilking
Publikováno v:
Medical Oncology. 21:309-318
Aim To compare the effects of tamoxifen and megestrol acetate on liver proteins, androgens, and glucocorticoids during adjuvant treatment for postmenopausal breast cancer. Methods A subgroup of women within a large prospective multicenter trial were
Autor:
Stig A. Larsson, Jonas Bergh, Hans Jacobsson, Elina Eriksson, E. von Schoultz, Brigitte Wilczek
Publikováno v:
Acta Radiologica. 44:284-287
Purpose: Response assessment at neoadjuvant (preoperative) chemotherapy of locally advanced breast cancer using clinical examination and mammography is insensitive. Mammoscintigraphy with 99mTc-MIBI was studied for the prediction of response at such
Autor:
Britt Masironi, E. Isaksson, Hong Wang, Lena Sahlin, E. von Schoultz, B. von Schoultz, J.M. Cline
Publikováno v:
The Breast. 11:295-300
The novel estrogen receptor ERbeta could be a key factor for proliferation and breast cancer risk. In a primate model for long-term HRT, surgically postmenopausal cynomolgus macaques were treated for 35 months with conjugated equine estrogens (CEE),
Autor:
Johan Hansson, L O Hansson, Ulrik Ringborg, E. Månsson Brahme, B. Nilsson, E. Djureen Mårtenson, E. von Schoultz
Publikováno v:
Journal of Clinical Oncology. 19:824-831
PURPOSE: To evaluate whether S-100B protein in serum is an independent prognostic marker in malignant melanoma. MATERIALS AND METHODS: S-100B protein in serum was analyzed in 1,007 consecutive patients with histologically verified cutaneous malignant